Use of an agent consisting of antibodies and/or insulin-like growth factor antagonists
The present invention relates to the use of a composition selected from the group consisting of antibodies, antibody fragments, insulin-like growth factor antagonists, Toll-like receptor antagonists and mixtures thereof for the treatment or the prophylaxis of certain diseases.
1. A method for treating periarthritis humero-scapularis comprising the step of administering orally to a subject in need thereof, a pharmaceutical preparation comprising an efficacious amount of IgY antibodies or their fragments, wherein said IgY antibodies or their fragments are anti-lipopolysaccharide polyclonal antibodies obtained from egg yolk of hens immunized with Gram-negative bacteria.
2. The method according to claim 1 , wherein the IgY antibodies or their fragments have been obtained from egg yolk powder.
3. The method according to claim 1 , wherein the IgY antibodies or their fragments have been obtained from dried defatted egg yolk powder.
4. The method according to claim 1 , wherein the preparation comprises anti-lipopolysaccharide IgY antibodies obtained from egg yolk of immunized chickens.
5. The method according to claim 1 , wherein the treatment is carried out by administering a daily dose of a formulation prepared for administration of 0.1- 10.0 g.
6. The method according to claim 1 , wherein the treatment is carried out by administering a daily dose of a formulation prepared for administration of 1.0- 8.0 g.
7. The method according to claim 1 , wherein the treatment is carried out by administering a daily dose of a formulation prepared for administration of 2.0- 7.0 g.
8. The method according to claim 1 , wherein the treatment is carried out by a daily administration for 4- 14 weeks.
9. The method according to claim 1 , characterized in that the periarthritis humero-scapularis is present in a patient further suffering from an idiopathic pain syndrome.
10. The method according to claim 1 , wherein the periarthritis humero-scapularis is present in a patient with a defective biological barrier against bacterial endotoxin.
11. The method according to claim 1 , wherein said IgY antibodies or their fragments represent at least 1.5 wt % based on the total weight of the preparation.
12. The method according to claim 1 , wherein said IgY antibodies or their fragments represent at least 2.0 wt % based on the total weight of the preparation.
13. The method according to claim 1 , wherein said IgY antibodies or their fragments represent at least 5.0 wt % based on the total weight of the preparation.
14. The method according to claim 1 , wherein said IgY antibodies or their fragments represent 100% of the total antibody content of the preparation.